Train harder · Free ship $75+ · Gear up now
Login Register
semaglutide and epilepsy

semaglutide and epilepsy New Study Suggests May Reduce Risk in Type 2 Diabetes Seizure Recurrence after GLP-1 Receptor

SKU: 1672116366

4.0
USD27.08 USD60.08

Pay in 4 interest-free payments of $6.77 Learn more

Shipping Estimate
USA
  • USA
  • CAN

Ships within 48 hours · Estimated delivery Aug 14 - Aug 19

Description

The trial currently has almost 10,000 patients enrolled and is expected to assess a composite MACE endpoint consisting of cardiovascular (CV) death, non-fatal myocardial infarction, or non-fatal stroke in patients with T2D as is expected to readout in July 2024 (NCT03574597)

semaglutide and epilepsy New Study Suggests May Reduce Risk in Type 2 Diabetes Seizure Recurrence after GLP-1 Receptor

Du, K., Ramachandran, A

semaglutide and epilepsy New Study Suggests May Reduce Risk in Type 2 Diabetes Seizure Recurrence after GLP-1 Receptor

B12: The Basics B12 is a water-soluble vitamin that plays a role in red blood cell formation, metabolism, immune health, DNA synthesis, and brain and nervous system functioning

semaglutide and epilepsy New Study Suggests May Reduce Risk in Type 2 Diabetes Seizure Recurrence after GLP-1 Receptor

doi: 10.1074/jbc.M116.731406 66 Moreno-DelgadoDPuigdellivolMMorenoERodriguez-RuizMBottaJGasperiniPet al

semaglutide and epilepsy New Study Suggests May Reduce Risk in Type 2 Diabetes Seizure Recurrence after GLP-1 Receptor
Exchange/Return Notes
  • We offer a 30-day return/exchange service after receiving.
  • Final sale items are not eligible for returns or exchanges.
  • To process your return/exchange, please contact us at [email protected]
  • Please click here for more details>>> Return & Exchange Policy

You may also like

recommand products